1. Introduction {#sec1-pharmaceuticals-13-00195}
===============

Hereditary hemochromatosis is a rare disorder of systemic iron overload due to deficiency of hepcidin, leading to intestinal iron hyperabsorption, and occurs in an autosomal recessive manner except for autosomal dominant type 4 hemochromatosis \[[@B1-pharmaceuticals-13-00195],[@B2-pharmaceuticals-13-00195],[@B3-pharmaceuticals-13-00195],[@B4-pharmaceuticals-13-00195]\]. Type 2A hemochromatosis is caused by homozygous mutations of *HJV* (*HFE2*), which encodes hemojuvelin, an essential regulator of the hepcidin expression. Unlike other hereditary hemochromatosis---which mostly occurs in individuals of \>30 years of age, rarer subtypes of *HJV*-related type 2A and *HAMP* (encoding hepcidin)-related type 2B hemochromatosis, which usually develop in the first to third decades of life---causes severe clinical complications, such as liver fibrosis, hepatocellular carcinoma, diabetes, hypogonadism, and heart failure; *HJV*-related type 2A hemochromatosis is referred to as juvenile hemochromatosis (JH) \[[@B1-pharmaceuticals-13-00195],[@B5-pharmaceuticals-13-00195]\].

The first line of therapy in hemochromatosis is iron removal by phlebotomy to prevent the progression of organ damage due to iron overload \[[@B4-pharmaceuticals-13-00195]\]. However, it has been suggested that iron removal by phlebotomy is generally insufficient for the treatment of JH. Although iron chelating agents, including orally administered agents that promote the mobilization and excretion of iron, have also been reported to be effective for removing iron, these agents may be associated with increased rates of adverse effects in comparison to phlebotomy \[[@B2-pharmaceuticals-13-00195],[@B3-pharmaceuticals-13-00195],[@B4-pharmaceuticals-13-00195]\]. Although substitutive hepcidin and agents stimulating the expression of hepcidin, such as antisense oligonucleotides and ferroportin antagonists, are also under development and are expected to be effective \[[@B6-pharmaceuticals-13-00195],[@B7-pharmaceuticals-13-00195],[@B8-pharmaceuticals-13-00195]\], these drugs are not clinically available at the present time. In order to develop safe and effective treatments for JH, it is important to better understand its clinical features.

We report the cases of two Japanese sisters with JH who showed the same homozygous *HJV* I281T mutation. Both patients showed a middle-aged onset and an indolent clinical course. In addition to these cases, homozygous *HJV* I281T has only been identified in one Greek patient of 39 years of age \[[@B9-pharmaceuticals-13-00195]\], raising the question whether the development and progression of JH may depend on the type of *HJV* mutation. In order to solve this question, we reviewed all reported cases of JH with homozygous mutations in *HJV*.

2. Results and Discussion {#sec2-pharmaceuticals-13-00195}
=========================

2.1. Case Report {#sec2dot1-pharmaceuticals-13-00195}
----------------

The proband (patient \#1) was a 38-year-old woman, who was referred to us due to a 1-year history of amenorrhea, thirst, and weight loss. The patient's laboratory findings showed high levels of transferrin saturation (93%), serum ferritin (2274 ng/mL) and alanine aminotransferase (51 U/L; reference range, 5--40), insulin-dependent diabetes, iron deposition of the anterior pituitary gland on nuclear magnetic resonance (NMR), with hypogonadism, and massive iron deposition in hepatocytes observed in a liver biopsy ([Table 1](#pharmaceuticals-13-00195-t001){ref-type="table"}). Phlebotomy effectively improved iron overload as a treatment of hemochromatosis to lead to a serum ferritin level \<50 ng/mL and has been continued for more than 19 years on an outpatient basis. Patient \#2 was a 55-year-old woman and the elder sister of patient \#1. Regardless of the diagnosis of hemochromatosis in patient \#1 (proband), she was referred to us due to liver dysfunction, dyslipidemia, and hyperglycemia for 3 years and thirst for 1 year. She was also found to have high levels of transferrin saturation (92%), serum ferritin (4340 ng/mL) and alanine aminotransferase (51 U/L), insulin-dependent diabetes, iron deposition of the pituitary gland was observed by NMR, with hypogonadism, and massive iron deposition in hepatocytes detected by liver biopsy, and cardiomyopathy with congestive heart failure, revealing the presence of hereditary hemochromatosis. Phlebotomy successfully improved the organ damage associated with iron overload, resulting in a serum ferritin level \<50 ng/mL and has been continued for more than 6 years on an outpatient basis. In both cases, the annual medical check-up did not point to abnormal function of organs including the liver.

2.2. Sequence Analysis of HJV and Family Tree {#sec2dot2-pharmaceuticals-13-00195}
---------------------------------------------

Two Japanese siblings were found to have JH with a homozygous mutation of *HJV* exon 4 (c.842 T \> C; p.I281T; rs74315326; [Figure 1](#pharmaceuticals-13-00195-f001){ref-type="fig"}a), and their serum levels of hepcidin were both below the limit of detection ([Table 1](#pharmaceuticals-13-00195-t001){ref-type="table"}). With the exception of the two patients, no individuals in the patients' family presented manifestations of hemochromatosis ([Figure 1](#pharmaceuticals-13-00195-f001){ref-type="fig"}b). Two sons (IV-5 and IV-6) of the proband who had a monoallelic *HJV* I281T did not show the phenotype of hemochromatosis, which was consistent with previous reports \[[@B10-pharmaceuticals-13-00195],[@B11-pharmaceuticals-13-00195]\]. The serum levels of hepcidin in IV-5 and IV-6 were not measured.

2.3. All Reported Cases of Juvenile Hemochromatosis {#sec2dot3-pharmaceuticals-13-00195}
---------------------------------------------------

As of July 1, 2020, 96 cases of JH with homozygous *HJV* mutations have been reported in 86 families ([Table 2](#pharmaceuticals-13-00195-t002){ref-type="table"}). Cases with compound heterozygous mutations of the *HJV* gene with non-*HJV* genes were excluded from this literature review. The median age at onset and age at the diagnosis in the 96 cases was 25 years (range, 4--60) and 26 years (range, 5--68), respectively. The median time from the onset to the diagnosis of JH was 4 years (range, 0--33). The median age at onset in females and males was 23 years (range, 5--60) and 26 years (range, 5--68) years, respectively, and the median age at the diagnosis was 26 years, regardless of sex (range, 5--68 in females and 16--51 in males), with no significant difference in either the age at the onset or the at the diagnosis. In addition, the female--male ratio of patients with JH was approximately 3:2 (58% *vs.* 42%). These findings may be in contrast to those of *HFE*-associated type 1 hemochromatosis, the most common subtype of hereditary hemochromatosis, which occurs equally in both sexes, in which the onset in females is later than that in males, possibly due to the loss of iron through menstrual bleeding in females \[[@B1-pharmaceuticals-13-00195],[@B12-pharmaceuticals-13-00195]\]. The age at the onset of JH did not differ between males and females, while females appeared to be more susceptible to the development of JH. One plausible explanation for these findings is that female hormones may promote iron overload in individuals with the homozygous *HJV* mutation. This hypothesis may be supported by a study \[[@B13-pharmaceuticals-13-00195]\] that showed that estradiol promoted iron absorption by directly repressing hepcidin transcription in the liver using a mouse model of hemochromatosis. Females with the homozygous *HJV* mutations who were \<30 years of age, who are prone to develop JH, may have high estradiol levels \[[@B14-pharmaceuticals-13-00195]\] and may, therefore, be more susceptible to the suppression of hepcidin than males, leading to the predominance of JH in females. However, in order to prove this hypothesis, the existence of asymptomatic carriers with homozygous *HJV* mutations and the predominance of these asymptomatic carriers in males must be proven, but these have not been identified.

2.4. Characteristics of Juvenile Hemochromatosis with Homozygous Identical Mutations in HJV {#sec2dot4-pharmaceuticals-13-00195}
-------------------------------------------------------------------------------------------

[Table 3](#pharmaceuticals-13-00195-t003){ref-type="table"} shows the sex and age of cases of JH with homozygous identical mutations in *HJV* in which 3 or more cases have been reported. When the patients---divided into eight groups according to the *HJV* mutations---were compared, using the group with the most frequent mutations of G320V/G320V (median age, 26 years) as a reference, the group with L101P/L101P mutations (median age, 13 years; *p* = 0.004) and the group with R385X/R385X mutations (median age, 15 years; *p* = 0.031) were significantly younger, and the group with I281T/I281T mutations (as observed in the current study) was significantly older (median age, 39 years; *p* = 0.010). Meanwhile, the median age of four cases of JH heterozygous for a single allele of *HJV* I281T, along with *HJV* C321X, C208X, and R6S mutations ([Table 2](#pharmaceuticals-13-00195-t002){ref-type="table"}), was 27 years, which was significantly younger in comparison to the group with I281T/I281T (*p* = 0.045) and was not significantly different from the group with G320V/G320V (*p* = 0.76). Accordingly, *HJV* I281T homozygosity may be necessary to delay the onset of JH. There were no significant sex differences among the eight groups. Aside from the current cases, *HJV* I281T homozygosity has only been identified in one Greek patient ([Table 1](#pharmaceuticals-13-00195-t001){ref-type="table"} and [Table 2](#pharmaceuticals-13-00195-t002){ref-type="table"}). This Greek patient developed JH at 39 years of age, was diagnosed at 49 years of age, and was the oldest among 12 cases (median age at onset, 27 years; range, 16--39 years) in a first report on *HJV* mutations in JH \[[@B9-pharmaceuticals-13-00195]\]. It was suggested that, unlike the typical *HJV* G320V mutation in JH, *HJV* I281T homozygosity may be associated with a middle-aged onset of JH; however, this is highly speculative because of the small number of cases.

The mechanisms through which the types of *HJV* mutation may affect the age of onset remains to be determined. Hemojuvelin is mainly expressed in the skeletal muscle, liver, and heart and has been shown to be an essential regulator of hepcidin from hepatocytes based on mouse model experiments \[[@B40-pharmaceuticals-13-00195],[@B41-pharmaceuticals-13-00195]\], which demonstrated that *HJV* knockout results in hemochromatosis through hepcidin deficiency. Membrane-bound hemojuvelin is necessary for hepcidin induction, whereas soluble-form hemojuvelin, cleaved by the serine protease matriptase-2, conversely suppresses the induction of hepcidin \[[@B42-pharmaceuticals-13-00195]\]. Previous studies \[[@B42-pharmaceuticals-13-00195],[@B43-pharmaceuticals-13-00195],[@B44-pharmaceuticals-13-00195]\] have confirmed that *HJV* mutations, as reported in JH, abolished the induction of hepcidin through two mechanisms: inhibition of the membrane export of hemojuvelin in biosynthesis and the decreased function of hemojuvelin itself, while the release of soluble hemojuvelin was not affected. The extent of these two mechanisms varies depending on the type of *HJV* mutation. It remains unknown how types of the *HJV* mutation suppresses the expression of hepcidin through these mechanisms.

The age of onset in six cases (three males and three females) of JH reported from Japan \[[@B19-pharmaceuticals-13-00195],[@B30-pharmaceuticals-13-00195]\], including the current study, was relatively high (median age, 44 years; range, 25--52), with a mostly benign course in which phlebotomy was effective in five of the six cases. Thus, the ethnicity and Japanese lifestyle of preferring vegetables and grains as well as green tea containing catechins that suppress the absorption of iron \[[@B45-pharmaceuticals-13-00195]\], rather than the type of the *HJV* mutation, might defer the onset of JH.

These results suggest that JH is more likely to occur in women in whom female hormones, especially estradiol, can promote iron overload. This may raise the hypothesis that treatment with estradiol-suppressing drugs would be effective for preventing the onset and progression of JH in individuals with the *HJV* homozygous mutations. Furthermore, it was shown that the type of *HJV* mutations may influence the age of onset of JH, suggesting that the sequencing of *HJV* may help predict the progression of organ damage. Besides, analyzing the function of *HJV* mutations may lead to the development of specific targeted therapies for JH.

2.5. Limitations {#sec2dot5-pharmaceuticals-13-00195}
----------------

One major limitation of this study is the lack of functional studies supporting the role of homozygous *HJV* mutations, such as *HJV* I281T, in affecting the development of hemochromatosis and, thus, the possibility that other unknown iron overload-related genes may be important causes of hemochromatosis was not excluded.

2.6. Strengths of the Present Study {#sec2dot6-pharmaceuticals-13-00195}
-----------------------------------

JH is caused by homozygous *HJV* gene mutations and has been thought to occur before 30 years of age, equally in both sexes. However, the current study found---through the second case report of two sibling JH cases with homozygous *HJV* I281T, who showed a middle-aged onset and an indolent course, as well as a review of the relevant literature on JH---that the type of *HJV* mutation and sex may be associated with the development of JH.

3. Materials and Methods {#sec3-pharmaceuticals-13-00195}
========================

3.1. Genetic Analysis for Hemochromatosis {#sec3dot1-pharmaceuticals-13-00195}
-----------------------------------------

All patients and their family members gave their written informed consent at the time of participating in the molecular studies, in accordance with the Declaration of Helsinki. This project was approved by the Institutional Review Boards of Kizawa Memorial Hospital and Asahikawa Medical University (\#15031). After obtaining written informed consent from each individual, blood samples were collected, then genomic DNA purification was performed, and the entire coding regions and splicing junctions of *HFE*, *HFE2 (HJV)*, *HAMP*, *TFR2*, and *SLC40A1* were sequenced according to a previous report \[[@B46-pharmaceuticals-13-00195]\]. Genetic mutations were then evaluated by comparing the sequencing results to open-access genetic information on the NCBI website. Serum hepcidin was measured by LC-MS/MS, as described previously \[[@B47-pharmaceuticals-13-00195]\], in findings provided by Medical Care Proteomics Biotechnology Co., Ltd. (Ishikawa, Japan).

3.2. Statistical Analyses {#sec3dot2-pharmaceuticals-13-00195}
-------------------------

The chi-squared test and Mann--Whitney test were used to compare the two groups. For the univariate analysis, two-tailed *p* values of \<0.05 were considered to indicate statistical significance.

4. Conclusions {#sec4-pharmaceuticals-13-00195}
==============

The current case report and review of the relevant literature revealed, for the first time, that JH developed in females and males at a ratio of 3:2, with no age difference between the two groups, and suggested that the age of onset of JH may depend on the type of *HJV* mutations. These findings may lead to the elucidation of the pathophysiology of JH and the development of novel therapeutic strategies.
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![The sequence analysis of *HJV* exon 4 of the proband (patient \#1) and the family tree. The homozygous missense mutation c.842T \> C, p.I281T (red arrow) is shown. (**a**). The proband (P: patient \#1) and the elder sister (patient \#2) developed hemochromatosis, while the other family members showed no manifestations of hemochromatosis. (**b**). III-2 and -3, *HJV* I281T/I281T; IV-5 and -6, *HJV* I281T/-. Arrows represent individuals who received a genetic analysis.](pharmaceuticals-13-00195-g001){#pharmaceuticals-13-00195-f001}

pharmaceuticals-13-00195-t001_Table 1

###### 

Characteristics of patients with homozygous I281T mutations in *HJV* (*HFE2*): the current and reported cases.

  No.                      1                                    2              3
  ------------------------ ------------------------------------ -------------- --------------
  Family no.               1                                    2              2
  Ref                      \[[@B9-pharmaceuticals-13-00195]\]   Current case   Current case
  Origin                   Greece                               Japan          Japan
  Allele                   I281T/I281T                          I281T/I281T    I281T/I281T
  Age at onset             39                                   37             52
  Age at Dx                49                                   38             55
  Sex                      NA                                   F              F
  Years post-Dx            NA                                   \>19           \>6
  Serum ferritin (ng/mL)   4127                                 2274           4340
  TSAT                     90%                                  93%            92%
  Hepcidin (ng/mL)         NA                                   BDL            BDL
  Hypogonadism             \+                                   \+             \+
  Arthropathy              \+                                   \+             \-
  Skin pigmentation        \+                                   \+             \+
  Glucose intolerance      \-                                   \+             \+
  Heart disease            \-                                   \-             \+
  Hepatic fibrosis         \+                                   \+             \+

Ref, reference; Dx, diagnosis; TSAT, transferrin saturation; F, female; M, male; +, present; -, absent; NA, not available; BDL, below detection limit.

pharmaceuticals-13-00195-t002_Table 2

###### 

Characteristics of patients with homozygous *HJV* mutations based on a review of the literature. Please note that cases with compound heterozygous mutations of the *HJV* gene with the non-*HJV* gene were excluded from this review.

  No.                            Family No.          Ref                                   Origin                   Allele                                Age at Onset   Age at Dx   Sex
  ------------------------------ ------------------- ------------------------------------- ------------------------ ------------------------------------- -------------- ----------- -----
  1                              1                   \[[@B9-pharmaceuticals-13-00195]\]    Greece                   I281T/I281T                           39             49          NA
  2                              2                   Current case                          Japan                    I281T/I281T                           37             38          F
  3                              2                   Current case                          Japan                    I281T/I281T                           52             55          F
  4                              3                   \[[@B10-pharmaceuticals-13-00195]\]   China                    I281T/C321X                           14             19          F
  5                              4                   \[[@B11-pharmaceuticals-13-00195]\]   China                    I281T/C321X                           26             26          M
  6                              4                   \[[@B11-pharmaceuticals-13-00195]\]   China                    I281T/C321X                           27             27          M
  7                              5                   \[[@B15-pharmaceuticals-13-00195]\]   China                    I281T/C208X/R6S                       35             36          F
  8                              6                   \[[@B9-pharmaceuticals-13-00195]\]    Canada                   I222N/G320V                           7              7           NA
  9                              7                   \[[@B9-pharmaceuticals-13-00195]\]    Greece                   G320V/G320V                           21             25          NA
  10                             8                   \[[@B9-pharmaceuticals-13-00195]\]    Greece                   G320V/G320V                           32             39          NA
  11                             9                   \[[@B9-pharmaceuticals-13-00195]\]    Greece                   G320V/G320V                           25             32          NA
  12                             10                  \[[@B9-pharmaceuticals-13-00195]\]    Greece                   G320V/G320V                           20             21          NA
  13                             11                  \[[@B9-pharmaceuticals-13-00195]\]    Greece                   C361fsX366/C361fsX366                 26             33          NA
  14                             12                  \[[@B9-pharmaceuticals-13-00195]\]    Greece                   G99V/G99V                             28             33          NA
  15                             13                  \[[@B9-pharmaceuticals-13-00195]\]    Greece                   G320V/G320V                           21             25          NA
  16                             14                  \[[@B9-pharmaceuticals-13-00195]\]    Greece                   G320V/R326X                           33             37          NA
  17                             15                  \[[@B9-pharmaceuticals-13-00195]\]    Greece                   G320V/G320V                           29             31          NA
  18                             16                  \[[@B9-pharmaceuticals-13-00195]\]    France                   G320V/G320V                           16             23          NA
  19                             17                  \[[@B11-pharmaceuticals-13-00195]\]   China                    C321X/H104R                           18             NA          M
  20                             18                  \[[@B11-pharmaceuticals-13-00195]\]   China                    C321X/V274M                           57             NA          M
  21                             19                  \[[@B11-pharmaceuticals-13-00195]\]   China                    Q312X/Q312X                           22             NA          F
  22                             20                  \[[@B11-pharmaceuticals-13-00195]\]   China                    F103L/F103L                           36             NA          F
  23                             21                  \[[@B16-pharmaceuticals-13-00195]\]   France (Caucasian)       G320V/G320V                           28             NA          M
  24                             22                  \[[@B16-pharmaceuticals-13-00195]\]   France (Caucasian)       G320V/G320V                           31             NA          M
  25                             23                  \[[@B16-pharmaceuticals-13-00195]\]   France (North African)   R385X/R385X                           8              NA          M
  26                             24                  \[[@B16-pharmaceuticals-13-00195]\]   France (Caucasian)       H180R/L101P                           60             NA          F
  27                             25                  \[[@B16-pharmaceuticals-13-00195]\]   France (Caucasian)       A384V/R288W                           32             NA          F
  28                             26                  \[[@B16-pharmaceuticals-13-00195]\]   France (Caucasian)       G320V/G320V                           16             NA          F
  29                             27                  \[[@B17-pharmaceuticals-13-00195]\]   African American         R54X/R54X                             4              23          M
  30                             28                  \[[@B18-pharmaceuticals-13-00195]\]   Romania                  G66X/G66X                             25             25          M
  31                             29                  \[[@B19-pharmaceuticals-13-00195]\]   Japan                    Y150C/V274M                           25             39          M
  32                             30                  \[[@B20-pharmaceuticals-13-00195]\]   United States            C80R/L101P                            18             23          F
  33                             31                  \[[@B20-pharmaceuticals-13-00195]\]   United States            C80R/L101P                            17             21          F
  34                             31                  \[[@B20-pharmaceuticals-13-00195]\]   United States            L101P/L101P                           13             23          F
  35                             31                  \[[@B20-pharmaceuticals-13-00195]\]   United States            L101P/L101P                           15             21          M
  36                             31                  \[[@B20-pharmaceuticals-13-00195]\]   United States            L101P/L101P                           12             18          F
  37                             31                  \[[@B20-pharmaceuticals-13-00195]\]   United States            L101P/L101P                           8              8           F
  38                             32                  \[[@B20-pharmaceuticals-13-00195]\]   United States            I222N/G320V                           17             23          F
  39                             33                  \[[@B21-pharmaceuticals-13-00195]\]   Bangladesh               C80Y/G320V                            NA             19          F
  40                             34                  \[[@B21-pharmaceuticals-13-00195]\]   Pakistan                 G99R/G99R                             NA             26          M
  41                             35                  \[[@B21-pharmaceuticals-13-00195]\]   Pakistan                 G99R/G99R                             NA             11          F
  42                             36                  \[[@B21-pharmaceuticals-13-00195]\]   Pakistan                 P192L/P192L                           NA             23          M
  43                             37                  \[[@B21-pharmaceuticals-13-00195]\]   Pakistan                 L194P/L194P                           NA             32          M
  44                             38                  \[[@B21-pharmaceuticals-13-00195]\]   Sri Lanka                A343PfsX23/A343PfsX23                 NA             17          M
  45                             39                  \[[@B22-pharmaceuticals-13-00195]\]   Australia                G320V/G320V                           NA             12          F
  46                             40                  \[[@B22-pharmaceuticals-13-00195]\]   Australia                C80R/R326X                            NA             18          F
  47                             41                  \[[@B22-pharmaceuticals-13-00195]\]   Australia                G320V/G320V                           NA             32          F
  48                             42                  \[[@B23-pharmaceuticals-13-00195]\]   Italy                    R385X/R385X                           15             NA          F
  49                             43                  \[[@B23-pharmaceuticals-13-00195]\]   Italy                    F170S/F170S                           20             NA          F
  50                             44                  \[[@B23-pharmaceuticals-13-00195]\]   Italy                    W191C/W191C                           21             NA          F
  51                             45                  \[[@B23-pharmaceuticals-13-00195]\]   Italy                    R385X/R385X                           20             NA          M
  52                             46                  \[[@B23-pharmaceuticals-13-00195]\]   Italy                    D149fsX245/D149fsX245                 20             NA          F
  53                             47                  \[[@B23-pharmaceuticals-13-00195]\]   Italy                    S205R/G250V                           21             NA          F
  54                             48                  \[[@B23-pharmaceuticals-13-00195]\]   Italy                    F170S/F170S                           14             NA          F
  55                             49                  \[[@B23-pharmaceuticals-13-00195]\]   Italy                    V74fsX113/N269fsX311                  24             NA          F
  56                             49                  \[[@B23-pharmaceuticals-13-00195]\]   Italy                    D149fsX245/D149fsX245                 21             NA          M
  57                             50                  \[[@B23-pharmaceuticals-13-00195]\]   Italy                    R131fsX245/R131fsX245                 20             NA          F
  58                             51                  \[[@B23-pharmaceuticals-13-00195]\]   Canada/Italy             G320V/G320V                           29             NA          M
  59                             52                  \[[@B23-pharmaceuticals-13-00195]\]   Italy                    S85P/S85P                             30             NA          F
  60                             53                  \[[@B23-pharmaceuticals-13-00195]\]   France                   R288W/R288W                           26             NA          F
  61                             54                  \[[@B23-pharmaceuticals-13-00195]\]   Italy                    D172E/G319fsX341                      20             NA          F
  62                             55                  \[[@B23-pharmaceuticals-13-00195]\]   Australia/English        A168D/A168D                           28             NA          M
  63                             56                  \[[@B23-pharmaceuticals-13-00195]\]   Albania                  L101P/G99R                            26             NA          F
  64                             57                  \[[@B23-pharmaceuticals-13-00195]\]   Italy                    D149fsX245/D149fsX245                 22             NA          M
  65                             58                  \[[@B23-pharmaceuticals-13-00195]\]   Canada/Italy             G320V/G320V                           27             NA          F
  66                             59                  \[[@B24-pharmaceuticals-13-00195]\]   Iran                     C89R/C89R                             26             26          M
  67                             59                  \[[@B24-pharmaceuticals-13-00195]\]   Iran                     C89R/C89R                             30             30          F
  68                             60                  \[[@B25-pharmaceuticals-13-00195]\]   English/Ireland          G320V/Q116X                           25             NA          F
  69                             61                  \[[@B26-pharmaceuticals-13-00195]\]   Croatia                  G320V/G320V                           NA             24          M
  70                             62                  \[[@B26-pharmaceuticals-13-00195]\]   Germany                  G320V/G320V                           NA             24          M
  71                             63                  \[[@B26-pharmaceuticals-13-00195]\]   Germany                  G320V/G320V                           NA             24          M
  72                             64                  \[[@B26-pharmaceuticals-13-00195]\]   Slovakia                 G320V/S328fsX337                      NA             25          M
  73                             64                  \[[@B26-pharmaceuticals-13-00195]\]   Slovakia                 G320V/S328fsX337                      NA             16          F
  74                             65                  \[[@B26-pharmaceuticals-13-00195]\]   Germany                  G320V/G320V                           NA             28          F
  75                             66                  \[[@B26-pharmaceuticals-13-00195]\]   Germany                  C119F/C119F                           NA             25          M
  76                             67                  \[[@B27-pharmaceuticals-13-00195]\]   Netherland               L165X/L165X                           NA             16          M
  77                             68                  \[[@B28-pharmaceuticals-13-00195]\]   France (Caucasian)       R176C/R176C                           NA             17          F
  78                             69                  \[[@B29-pharmaceuticals-13-00195]\]   France                   G320V/R176C                           5              5           F
  79                             70                  \[[@B30-pharmaceuticals-13-00195]\]   Japan                    D249H/D249H                           48             48          M
  80                             71                  \[[@B30-pharmaceuticals-13-00195]\]   Japan                    Q312X/Q312X                           51             51          M
  81                             72                  \[[@B30-pharmaceuticals-13-00195]\]   Japan                    Q312X/Q312X                           51             51          F
  82                             73                  \[[@B31-pharmaceuticals-13-00195]\]   Caucasian                G320V/C321W                           23             30          F
  83                             74                  \[[@B32-pharmaceuticals-13-00195]\]   India                    D355Y/D355Y                           35             42          M
  84                             74                  \[[@B32-pharmaceuticals-13-00195]\]   India                    D355Y/D355Y                           28             32          M
  85                             75                  \[[@B33-pharmaceuticals-13-00195]\]   Romania                  G320V/G320V                           27             31          F
  86                             76                  \[[@B34-pharmaceuticals-13-00195]\]   Caucasian                G320V/G320V                           20             39          F
  87                             77                  \[[@B35-pharmaceuticals-13-00195]\]   Italy                    C317S/C317S                           35             68          F
  88                             78                  \[[@B36-pharmaceuticals-13-00195]\]   India                    G336X/G336X                           NA             45          M
  89                             79                  \[[@B36-pharmaceuticals-13-00195]\]   India                    G336X/G336X                           NA             49          F
  90                             80                  \[[@B36-pharmaceuticals-13-00195]\]   India                    G336X/G336X                           NA             38          F
  91                             81                  \[[@B36-pharmaceuticals-13-00195]\]   India                    G336X/G336X                           NA             47          M
  92                             82                  \[[@B36-pharmaceuticals-13-00195]\]   India                    5'UTR -358 (G\>A)/ 5'UTR -36 (G\>A)   NA             43          M
  93                             83                  \[[@B36-pharmaceuticals-13-00195]\]   India                    5'UTR -358 (G\>A)/ 5'UTR -36 (G\>A)   NA             32          F
  94                             84                  \[[@B37-pharmaceuticals-13-00195]\]   China                    C321X/Q6H                             23             31          M
  95                             85                  \[[@B38-pharmaceuticals-13-00195]\]   English/Ireland          L28SfsX24/ L28SfsX24                  25             25          F
  96                             86                  \[[@B39-pharmaceuticals-13-00195]\]   Brazil                   Q233fsX245/Q233fsX245                 26             26          F
                                                                                                                                                                                     
  Total, F/M                     49 (58%)/35 (42%)                                                                                                                                   
  Median age (total)             25                  26                                                                                                                              
  Median age (F)                 23                  26                                                                                                                              
  Range (F)                      5--60               5--68                                                                                                                           
  Median age (M)                 26                  26                                                                                                                              
  Range (M)                      4--57               16--51                                                                                                                          
  *P* value at age (F *vs.* M)   0.47                0.48                                                                                                                            
  Standard deviation (total)     11                  12                                                                                                                              
  Standard deviation (F)         11                  14                                                                                                                              
  Standard deviation (M)         12                  10                                                                                                                              

Ref, reference; F, Female; M, Male; NA, not available; 5'UTR, 5'prime untranslated region.

pharmaceuticals-13-00195-t003_Table 3

###### 

Relationship of the *HJV* mutation with sex and the age of onset in JH patients with homozygous identical mutations in *HJV* (limited to mutations with ≥3 reported cases).

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Group Number   Allele                  Origin (Number of Cases)                                                                                  Number of Cases   Sex, F/M   Median Age, y   Minimum, y   Maximum, y   *p* Value at Age vs. G320V\
                                                                                                                                                                                                                          /G320V
  -------------- ----------------------- --------------------------------------------------------------------------------------------------------- ----------------- ---------- --------------- ------------ ------------ -----------------------------
  **1**          G320V/G320V             Greece (6), France (4), Germany (3), Canada (2), Australia (2), Romania (1), Croatia (1), Caucasian (1)   20                7/6        26              16           32           Reference

  **2**          G336X/G336X             India (4)                                                                                                 4                 2/2        NA              NA           NA           NA

  **3**          L101P/L101P             United states (4)                                                                                         4                 3/1        13              8            15           0.004

  **4**          I281T/I281T             Japan (2), Greece (1)                                                                                     3                 2/0        39              37           52           0.010

  **5**          Q312X/Q312X             Japan (2), China (1)                                                                                      3                 2/1        51              22           51           0.105

  **6**          D149fsX245/D149fsX245   Italy (3)                                                                                                 3                 1/2        21              20           22           0.498

  **7**          G99R/G99R               Pakistan (2), Greece (1)                                                                                  3                 1/1        28              28           28           0.708

  **8**          R385X/R385X             Italy (2), France (1)                                                                                     3                 1/2        15              8            20           0.031
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

F, female; M, male; NA, not available. Bold typeface represents a significant difference.
